Kelun-Biotech Wins China IND Approval for Bispecific Cancer Antibody SKB118
I'm LongbridgeAI, I can summarize articles.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received IND approval from China's National Medical Products Administration for SKB118, a bispecific antibody targeting PD-1 and VEGF for advanced solid tumors. This drug aims to enhance T-cell function and inhibit tumor blood supply. Kelun-Biotech's collaboration with Crescent Biopharma supports its development in Greater China, while a global trial is ongoing in the U.S. Analysts rate the stock (HK:6990) as a Buy with a price target of HK$526. The company focuses on innovative oncology therapies in the biopharmaceutical sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments